High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?

International Angiology

Volumn 22, Issue 1, 2003, Pages 15-23

  Sellmayer, Alois ^a   Limmert, T ^a   Hoffmann, U ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

C reactive protein; Cardiovascular diseases, etiology; Inflammation; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; PROGESTERONE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; MENOPAUSAL SYNDROME; PERIPHERAL VASCULAR DISEASE; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT;

ARTERIOSCLEROSIS; ASPIRIN; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 0037710313     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Wilson PW, D'Agostino RB, Levy D, Belanger SM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
2. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular M,nster (PROCAM) study Circulation 2002;105:310-5.
3. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics. Arch Intern Med 2001;161:2657-60.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J et al. Evaluation of 9 automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-25.
6. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000;21:1574-83.
7. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
8. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
9. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PWM, Li RK et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
10. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
11. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacol 1999;190:585-90.
12. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is FCγ receptor II. J Exp Med 1999;190:585-90.
13. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation 2001;103:1194-7.
14. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6.
15. Torzewski J, Torzewksi M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.
16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
17. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
18. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
19. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
21. König W, Sund M, Fröhlich M, Fischer HG, Löweö H, Döring A et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999;99:237-42.
22. Danesh J, Whincup, P, Walker M, Lennon L, Thomson A, Appleby P et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. Br Med J 2000;321:199-204.
23. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-7.
24. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
25. Tracy RP, Lemaitr RN, Psaty BM, Ives DG, Evans RW, Cushman M et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
26. Lagrand WK, Visser CA, Hermens WT, Niessen HWM, Verheugt FWA, Wolbink GJ et al. C-reactive protein as a cardiovascular risk factor. Circulation 1999;100:96-102.
27. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001;104:63-7.
28. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000;20:1057-60.
29. Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Després JP et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001;161:2474-80.
30. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996;312:1061-5.
31. Tracy RP, Psaty BM, Ives DG, Macy E, Bovill EG, Cushman M et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997;17:2167-76.
32. De Maat MP, Kluft C. Determinants of C-reactive protein concentration in human blood. Ital Heart J 2001;2:189-95.
33. Kushner I. C-reactive protein (CRP) elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001;68:535-7.
34. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
35. Ford EA. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971-7.
36. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Böing H et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000;23:1835-9.
37. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-70.
38. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9.
39. Ridker PM, Henneknes CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-6.
40. Barinas-Mitchell E, Cushman M, Meilhahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001;153:1094-101.
41. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. Circulation 1999;100:717-22.
42. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000;9:37-41.
43. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41.
44. Ikonomidis I, Adreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
45. Kennon S, Price CP, Mills PG, Ranjadayalan K, Cooper J, Clarke H et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001;37:1266-70.
46. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 2002;136:161-72.
47. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
48. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, CARE Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
49. Ridker PM, Rifai N, Pitman Lowenthal S. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
50. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. JAMA 2001;286:64-70.
51. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-9.
52. Kushner I, Sehgal AR. Is high sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 2002;162:867-9.
53. Levinson SS, Elin RJ. What is C-reactive protein telling us about coronary artery disease? Arch Intern Med 2002;162:389-92.
54. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.